【摘要】 目的系统评价当归饮子治疗慢性荨麻疹的疗效与安全性。方法计算机检索PubMed、Cochrane图书馆、SCI、EMbase、VIP、CNKI和CBM,查找当归饮子治疗慢性荨麻疹的随机对照试验,检索时限均从建库至2011年7月。由2名研究者按照纳入与排除标准独立进行文献筛选、资料提取和质量评价后,采用RevMan 5.0.2软件进行Meta分析。结果纳入11个RCT,共1 081例患者。Meta分析结果显示,当归饮子治疗慢性荨麻疹的好转率优于氯雷他定、地氯雷他定、赛庚啶,孟鲁司特和其他中药+西替利嗪+西米替丁好转率优于氯雷他定、西替利嗪、赛庚啶、地氯雷他定、其他中药+卡介苗杆菌和其他中药+西替利嗪+西米替丁,且较常规抗组胺药物能降低随访3个月的复发率[OR=0.43,95%CI(0.22,0.82),P=0.01],但缺乏患者生活质量指标比较的数据。在不良反应方面,尚未见当归饮子的严重不良反应报告。结论本系统评价结果显示,与常规抗组胺治疗相比,当归饮子有更好的治愈率和好转率,且能降低随访3个月的复发率。但由于纳入文献数量较少,质量较低,当前证据尚不能确定完全适用于临床,但其疗效优势值得进一步研究,特别需要高质量的多中心大样本随机双盲对照试验来验证。更多还原

【Abstract】 Objective To evaluate the effectiveness and safety of Chinese angelica decoction (CAD) versus conventional treatment (CT) for chronic urticaria (CU). Methods Systematic searches were conducted in PubMed, The Cochrane Library, SCI, EMbase, VIP, CNKI and CBM to collect randomized controlled trials (RCTs) on CAD treating CU from inception to July 2011. Two reviewers independently screened articles according to the inclusion and exclusion criteria, extracted data and evaluated the quality of the included studies. Then meta-analysis was performed using RevMan 5.0.2. Results A total of 11 RCTs involving 1081 patients were included. The results of meta-analysis demonstrated that compared with the CT group (antihistamine therapy), CAD seemed higher in the cure rate (OR=2.36, 95%CI 1.80 to 3.10, I2=22%, P<0.00001), improvement rate (OR=4.56, 95%CI 2.65 to 7.87, I2=0%, P<0.00001), and lower in the relapse rate at the third month after the treatment (OR=0.43, 95%CI 0.22 to 0.82, I2=0%, P=0.01). No study reported the quality of life and severe adverse reactions after CAD treatment. Conclusion Current evidence shows CAD may be superior to CT in treating CU patients. However, due to lack of enough high-quality studies, CAD has to be further studied by conducting more strictly-designed, multicenter, large-scale and double-blind RCTs.更多还原